Elizabeth Anderson
Stock Analyst at Evercore ISI Group
(2.43)
# 2,474
Out of 5,131 analysts
136
Total ratings
51.19%
Success rate
-1.16%
Average return
Main Sectors:
Stocks Rated by Elizabeth Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDLN Medline | Initiates: Outperform | $50 | $42.76 | +16.93% | 1 | Jan 12, 2026 | |
| FTRE Fortrea Holdings | Upgrades: Outperform | $14 → $25 | $18.40 | +35.87% | 11 | Jan 6, 2026 | |
| PRVA Privia Health Group | Maintains: Outperform | $28 → $30 | $23.44 | +28.01% | 5 | Nov 7, 2025 | |
| OMDA Omada Health | Maintains: Outperform | $27 → $28 | $16.00 | +75.00% | 1 | Nov 7, 2025 | |
| DOCS Doximity | Maintains: Outperform | $81 → $70 | $44.03 | +58.98% | 10 | Nov 7, 2025 | |
| HSIC Henry Schein | Maintains: Outperform | $83 → $90 | $76.13 | +18.22% | 2 | Nov 5, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $190 → $220 | $208.65 | +5.44% | 10 | Oct 31, 2025 | |
| TDOC Teladoc Health | Maintains: In-Line | $9 → $8 | $7.36 | +8.70% | 6 | Oct 30, 2025 | |
| CVS CVS Health | Maintains: Outperform | $85 → $95 | $80.55 | +17.94% | 10 | Oct 30, 2025 | |
| ALGN Align Technology | Maintains: Outperform | $160 → $170 | $171.74 | -1.01% | 15 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $17 → $13 | $12.66 | +2.69% | 8 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $220 → $240 | $242.46 | -1.01% | 7 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $65 | $48.58 | +33.80% | 2 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $4 → $3 | $2.43 | +23.46% | 9 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $185 → $190 | $175.94 | +7.99% | 4 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $305 | $250.39 | +21.81% | 7 | Oct 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $800 → $825 | $826.00 | -0.12% | 7 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $23 | $23.50 | -2.13% | 4 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $5 → $3 | $0.99 | +203.34% | 5 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $36 | $31.25 | +15.20% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $68 → $26 | $2.40 | +993.75% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $35 → $15 | $3.99 | +275.94% | 3 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 | $1.69 | +550.89% | 2 | Jan 4, 2022 |
Medline
Jan 12, 2026
Initiates: Outperform
Price Target: $50
Current: $42.76
Upside: +16.93%
Fortrea Holdings
Jan 6, 2026
Upgrades: Outperform
Price Target: $14 → $25
Current: $18.40
Upside: +35.87%
Privia Health Group
Nov 7, 2025
Maintains: Outperform
Price Target: $28 → $30
Current: $23.44
Upside: +28.01%
Omada Health
Nov 7, 2025
Maintains: Outperform
Price Target: $27 → $28
Current: $16.00
Upside: +75.00%
Doximity
Nov 7, 2025
Maintains: Outperform
Price Target: $81 → $70
Current: $44.03
Upside: +58.98%
Henry Schein
Nov 5, 2025
Maintains: Outperform
Price Target: $83 → $90
Current: $76.13
Upside: +18.22%
Cardinal Health
Oct 31, 2025
Maintains: Outperform
Price Target: $190 → $220
Current: $208.65
Upside: +5.44%
Teladoc Health
Oct 30, 2025
Maintains: In-Line
Price Target: $9 → $8
Current: $7.36
Upside: +8.70%
CVS Health
Oct 30, 2025
Maintains: Outperform
Price Target: $85 → $95
Current: $80.55
Upside: +17.94%
Align Technology
Oct 30, 2025
Maintains: Outperform
Price Target: $160 → $170
Current: $171.74
Upside: -1.01%
Oct 8, 2025
Maintains: In-Line
Price Target: $17 → $13
Current: $12.66
Upside: +2.69%
Oct 8, 2025
Maintains: Outperform
Price Target: $220 → $240
Current: $242.46
Upside: -1.01%
Oct 8, 2025
Maintains: Outperform
Price Target: $60 → $65
Current: $48.58
Upside: +33.80%
Oct 8, 2025
Maintains: In-Line
Price Target: $4 → $3
Current: $2.43
Upside: +23.46%
Oct 8, 2025
Maintains: In-Line
Price Target: $185 → $190
Current: $175.94
Upside: +7.99%
Oct 3, 2025
Maintains: Outperform
Price Target: $300 → $305
Current: $250.39
Upside: +21.81%
Sep 24, 2025
Maintains: Outperform
Price Target: $800 → $825
Current: $826.00
Upside: -0.12%
Jul 9, 2025
Maintains: Outperform
Price Target: $19 → $23
Current: $23.50
Upside: -2.13%
Jul 9, 2025
Maintains: In-Line
Price Target: $5 → $3
Current: $0.99
Upside: +203.34%
Nov 7, 2024
Maintains: Outperform
Price Target: $32 → $36
Current: $31.25
Upside: +15.20%
Mar 16, 2022
Maintains: In-Line
Price Target: $68 → $26
Current: $2.40
Upside: +993.75%
Mar 2, 2022
Downgrades: In-Line
Price Target: $35 → $15
Current: $3.99
Upside: +275.94%
Jan 4, 2022
Downgrades: In-Line
Price Target: $11
Current: $1.69
Upside: +550.89%